{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:53:30Z","timestamp":1732035210228},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,8,31]],"date-time":"2014-08-31T00:00:00Z","timestamp":1409443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec><jats:label \/><jats:p>Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of the hematopoietic stem cell that is exceptionally rare in the first five years of life, particularly as a secondary malignancy. This report describes a case of secondary CML in a four\u2010year\u2010old female occurring after AML treatment. Interestingly, CML developed while on immunosuppression for a heart transplant due to anthracycline\u2010induced cardiomyopathy. Pediatr Blood Cancer 2015;62:166\u2013168. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.25204","type":"journal-article","created":{"date-parts":[[2014,8,31]],"date-time":"2014-08-31T15:33:05Z","timestamp":1409499185000},"page":"166-168","source":"Crossref","is-referenced-by-count":9,"title":["Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline\u2010induced cardiomyopathy"],"prefix":"10.1002","volume":"62","author":[{"given":"Neethu Mohan","family":"Menon","sequence":"first","affiliation":[{"name":"Department of Pediatrics University of Arizona Tucson Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology Oncology and BMT, University of Arizona Tucson Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain","family":"Khalpey","sequence":"additional","affiliation":[{"name":"Heart Transplant Program University of Arizona Tucson Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja","family":"Whitlow","sequence":"additional","affiliation":[{"name":"Center for Cancer, Blood Institute Cincinnati Children's Hospital Medical Center Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,31]]},"reference":[{"key":"e_1_2_4_2_1","volume-title":"SEER cancer statistics review, 1975\u20132005","author":"Ries LAG"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.692788"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809058378"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050527"},{"key":"e_1_2_4_6_1","first-page":"623","article-title":"Chronic myeloid leukemia following heart transplantation and immunosuppression with tacrolimus","volume":"9","author":"Sbenghe MM","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_4_8_1","first-page":"461","article-title":"Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia","volume":"27","author":"Li J","year":"2012","journal-title":"Oncol Rep"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08472.x"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09105-2"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000343952"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-467787"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2007.05.018"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01357.x"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480200900205"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.132"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2006.06.008"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2003.08.014"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.03.014"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(94)90402-2"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.25204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.25204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T18:18:01Z","timestamp":1696529881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.25204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,31]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1002\/pbc.25204"],"URL":"https:\/\/doi.org\/10.1002\/pbc.25204","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,31]]}}}